
About Recce Pharmaceuticals
Recce Pharmaceuticals is a publicly listed company based in Sydney (Australia) founded in 2007. Antibiotics for drug-resistant bacteria and cancer treatments are developed. It operates on a HealthTech model. Its chief executive, as recorded, is James Graham. Recce Pharmaceuticals offers products and services including Synthetic Anti-Infectives, Intravenous Sepsis Treatment, and Topical ABSSSI Treatment. Its focus areas include Pharmaceuticals and Anti-Infectives. Its legal entity is Recce Pharmaceuticals Ltd.
Company details
Recce Pharmaceuticals Ltd is engaged in the development of a new class of synthetic anti-infectives aimed at addressing the global challenge of antibiotic-resistant superbugs. The company operates in the healthcare sector, focusing on solutions for bacterial and viral infections. Multiple clinical indications and formulations are being pursued, including Phase I and II trials, as well as a registrational Phase III trial in Indonesia. Their proprietary anti-infectives are designed with a universal mechanism of action to overcome hyper-cellular mutations in bacteria and viruses.
- Headquarters Sydney, Australia
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website recce.com.au
- Social LinkedIn X Instagram YouTube
- Legal Name Recce Pharmaceuticals Ltd
- Net Profit-$10.3 M (USD)30.18as on Jun 30, 2026
- EBITDA-$15.71 M (USD)17.51as on Jun 30, 2026
- Latest Funding Round$4.76M (USD), Post-IPO
Jun 2025
Products & Services of Recce Pharmaceuticals
Recce Pharmaceuticals offers a comprehensive portfolio of products and services, including Synthetic Anti-Infectives, Intravenous Sepsis Treatment, and Topical ABSSSI Treatment.
Synthetic anti-infectives are developed to combat resistant bacteria.
Intravenous treatment for sepsis is being clinically tested.
Topical treatment for ABSSSI is under clinical development.
Apps and channels of Recce Pharmaceuticals
its YouTube channel Recce Pharmaceuticals has 153 subscribers and 30 videos.
Videos from Recce Pharmaceuticals
The most watched videos on Recce Pharmaceuticals's YouTube channel, Recce Pharmaceuticals (153 subscribers). Click a video to play it here.
More on Recce Pharmaceuticals.
Funding Insights of Recce Pharmaceuticals
- Total Rounds 5
- Last Round Post-IPO β $4.76M
- First Round $1.28M
(Feb 2019)
All 5 funding rounds of Recce Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2025 | $4.76M | Post-IPO | β | β | β |
| Apr 2025 | $10.11M | Post-IPO | β | β | β |
| Sep 2020 | $20.11M | Post-IPO | β | β | β |
| Oct 2019 | $4.56M | Post-IPO | β | β | β |
| Feb 2019 | $1.28M | Post-IPO | β | β | β |
People of Recce Pharmaceuticals
15 people are tracked at Recce Pharmaceuticals (6 in leadership, 4 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
James Graham | CEO | Leadership |
Justin Reynolds | Chief Financial Officer | Leadership |
Michele Dilizia | Executive Director & Chief Scientific Officer | Leadership |
Andre Serobian | Commercial Director | Leadership |
Cherise A. | Vice President Of Corporate Affairs | Leadership |
Peter McCray | Head Of Operations | Leadership |
John Prendergast | Non-Executive Chairman | Board & advisors |
Alan Dunton | Non-Executive Director | Board & advisors |
David Bowers | Chair of Clinical Advisory Committee | Board & advisors |
Philip Sutton | Clinical Advisory Committee Member | Board & advisors |
Daniel Astudillo | Marketing Manager | Team |
Simone Messenger | Executive Assistant | Team |
Thomas Skinner | Senior Marketing Manager | Team |
Michelle Corke | Office Manager | Team |
Amanda Giovanelli | Marketing Specialist | Team |
Complete people profiles for Recce Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Recce Pharmaceuticals
Recce Pharmaceuticals is a publicly listed company on the ASX with ticker symbol RCE in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Jan 2016
- Listed onASX: RCE
- Listed entityRECCE PHARMACEUTICALS LTD
- Exchange sectorHealth technology
- ISINAU000000RCE5
- Share price0.29 AUD (+9.43% on the day) · 2026-10-14
- Market capitalisation81,029,059.00 AUD
- EPS (diluted, trailing year)-0.05 AUD
- Volume (last session)43,027
Financials of Recce Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | -15.0M AUD | -22.8M AUD | |
| 2025 | -21.4M AUD | -27.6M AUD | |
| 2024 | -17.7M AUD | -21.7M AUD | |
| 2023 | -13.1M AUD | -17.1M AUD | |
| 2022 | -11.0M AUD | -14.0M AUD |
Detailed financial statements for Recce Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Recce Pharmaceuticals
4 dated milestones of Recce Pharmaceuticals across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Recce Pharmaceuticals is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.3M.
- Funding Latest funding round, Post-IPO, of $4.8M.
Web traffic of Recce Pharmaceuticals
The website of Recce Pharmaceuticals (recce.com.au) receives about 3.4K visits a month.
- Monthly visits3.4K
▼ 45.4% vs previous month
Websites whose visitors overlap most with Recce Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ginzalimited.com | 100% | 3.6K | #4,922,195 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Recce Pharmaceuticals
Complete news archive for Recce Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recce Pharmaceuticals
Recce Pharmaceuticals was founded in 2007 and raised its 1st funding round 12 years after it was founded.
Recce Pharmaceuticals is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.
James Graham is the CEO of Recce Pharmaceuticals, as recorded in our data.
Recce Pharmaceuticals Ltd is engaged in the development of a new class of synthetic anti-infectives aimed at addressing the global challenge of antibiotic-resistant superbugs. The company operates in the healthcare sector, focusing on solutions for bacterial and viral infections. Multiple clinical indications and formulations are being pursued, including Phase I and II trials, as well as a registrational Phase III trial in Indonesia. Their proprietary anti-infectives are designed with a universal mechanism of action to overcome hyper-cellular mutations in bacteria and viruses.
Recce Pharmaceuticals offers Synthetic Anti-Infectives, Intravenous Sepsis Treatment, and Topical ABSSSI Treatment.
Yes, Recce Pharmaceuticals is publicly traded on ASX under the ticker symbol RCE.
Recce Pharmaceuticals operates through Recce Pharmaceuticals Ltd.
